- Vincristine
- Vincristine sulfate
- 57227-09-5Benzenepropanamide, a-(benzoylamino)-4-hydroxy-N,N-dipropyl-
- 5722-93-02-HYDROXY-4,5-DIMETHOXY BENZOIC ACID
- 57229-67-1L-Tryptophan,N-[(1,1-dimethylethoxy)carbonyl]-, phenylmethyl ester
- 572-30-54H-1-Benzopyran-4-one,3-(a-L-arabinofuranosyloxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
- 57231-31-96,7-Isoquinolinediol,1-[(3,4-dihydroxyphenyl)methyl]-1,2,3,4-tetrahydro-2-methyl-, (1S)-
- 572-31-64H-1-Benzopyran-4-one,3-[(6-deoxy-α-L-mannopyranosyl)oxy]-2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-,(2R,3R)-
- 57233-86-0Benzenemethanamine, a-methyl-4-nitro-, hydrochloride(1:1), (aR)-
- 57235-35-52(1H)-Pyrimidinethione,4,6-dimethoxy-
- 57235-50-41,3,4-Thiadiazol-2-amine,5-cyclopropyl-
- 57238-75-21,2,4-Oxadiazole,5-(chloromethyl)-3-(4-chlorophenyl)-
Hot Products
- 52-67-5D-Valine, 3-mercapto-
- 7447-39-4Cupric chloride
- 42615-29-2Linear alkyl benzenesulphonate
- 593-29-3Potassium stearate
- 1112-39-6Silane,dimethoxydimethyl-
- 14028-44-5Dibenz[b,f][1,4]oxazepine,2-chloro-11-(1-piperazinyl)-
- 70977-72-9Ethanone,1-(3-amino-2-hydroxyphenyl)-
- 874-42-02,4-Dichlorobenzaldehyde
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Vincristine |
EINECS | 200-318-1 |
| CAS No. | 57-22-7 | Density | 1.406 g/cm3 |
| PSA | 171.17000 | LogP | 4.09420 |
| Solubility | N/A | Melting Point |
211-216 °C |
| Formula | C46H56N4O10 | Boiling Point | 761.92°C (rough estimate) |
| Molecular Weight | 824.971 | Flash Point | N/A |
| Transport Information | N/A | Appearance | a white crystalline solid |
| Safety | Risk Codes | N/A | |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
(+)-Vincristine;22-Oxovincaleukoblastine;Leucristine;OncoTCS;VCR;Vincristin;Vinkristin;Leurocristine(7CI,8CI); |
Article Data | 3 |
Vincristine Synthetic route
| Conditions | Yield |
|---|---|
| With sodium carbonate In methanol; chloroform; water | 98% |
- 101156-38-1
cyclovincristine
- 57-22-7
Vincristine
| Conditions | Yield |
|---|---|
| With sodium tetrahydroborate In dichloromethane; acetic acid for 2h; Ambient temperature; | 79% |
- 38390-45-3, 56083-20-6, 61246-76-2, 105815-31-4
anhydrovinblastine
A
- 57-22-7
Vincristine
C
- 363623-08-9, 906333-70-8
vinblastin
D
- 23360-92-1
vinleurosine
| Conditions | Yield |
|---|---|
| With cell-free extracts from Catharanthus roseus Product distribution; Mechanism; Ambient temperature; biosynthesis of the products were studied; experiment was performed with 3',4'-anhydrovinblastine and the incorporation of the radiolabel into the products were investigated; |
| Conditions | Yield |
|---|---|
| With 1,8-diazabicyclo[5.4.0]undec-7-ene In methanol at 20℃; for 48h; | 70% |
| Conditions | Yield |
|---|---|
| In tetrahydrofuran at 20℃; for 3h; | 68% |
- 57-22-7
Vincristine
| Conditions | Yield |
|---|---|
| Stage #1: Vincristine With 3-chloro-benzenecarboperoxoic acid In dichloromethane at 0℃; for 0.0333333h; Stage #2: With sodium carbonate In dichloromethane; water | 67% |
| Conditions | Yield |
|---|---|
| In tetrahydrofuran at 20℃; for 3h; | 67% |
| Conditions | Yield |
|---|---|
| In tetrahydrofuran at 20℃; for 3h; | 65% |
| Conditions | Yield |
|---|---|
| Stage #1: trifluoromethylsulfonic anhydride; C13H17N3O3 With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at -78℃; for 0.833333h; Inert atmosphere; Stage #2: Vincristine In tetrahydrofuran at -78℃; for 1.33333h; Inert atmosphere; | 57% |
- 57-22-7
Vincristine
- 101156-38-1
cyclovincristine
| Conditions | Yield |
|---|---|
| With chromium(VI) oxide; acetic anhydride In methanol; dichloromethane; acetic acid at -20℃; for 17h; | 46% |
Vincristine Consensus Reports
NCI Carcinogenesis Studies (ipr); No Evidence: mouse, rat CANCAR Cancer. 40 (1977),1935. . EPA Genetic Toxicology Program.
Vincristine Specification
The Vincristine, with the CAS registry number 57-22-7, is also known as Vincaleukoblastine, 22-oxo-, (3β,4'β)-. It belongs to the classification codes of Antimitotic Agents; Antineoplastic Agents; AntineoplasticAagents, Phytogenic; Drug / Therapeutic Agent; Human Data; Mitosis Modulators; Mutation Data; Natural Product; Reproductive Effect; Skin / Eye Irritant; Tubulin Modulators; Tumor Data. Its EINECS registry number is 200-318-1. This chemical's molecular formula is C46H56N4O10 and molecular weight is 824.96. What's more, its IUPAC name is called (2α,2'β,3α,4α,5β,19β)-22-Oxovincaleukoblastine. It is a mitotic inhibitor, and is used in cancer chemotherapy. Vincristine is created by the coupling of indole alkaloids vindoline and catharanthine in the vinca plant.
Physical properties about Vincristine are: (1)ACD/LogP: 5.749; (2)# of Rule of 5 Violations: 3; (3)ACD/LogD (pH 5.5): 3.15; (4)ACD/LogD (pH 7.4): 5.20; (5)ACD/BCF (pH 5.5): 34.56; (6)ACD/BCF (pH 7.4): 3920.85; (7)ACD/KOC (pH 5.5): 80.12; (8)ACD/KOC (pH 7.4): 9090.30; (9)#H bond acceptors: 14; (10)#H bond donors: 3; (11)#Freely Rotating Bonds: 12; (12)Polar Surface Area: 171.17 Å2; (13)Index of Refraction: 1.677; (14)Molar Refractivity: 221.088 cm3; (15)Molar Volume: 586.859 cm3; (16)Polarizability: 87.646×10-24cm3; (17)Surface Tension: 74.056 dyne/cm; (18)Density: 1.406 g/cm3.
You can still convert the following datas into molecular structure:
(1) SMILES: O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C=O)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC
(2) InChI: InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
(3) InChIKey: OGWKCGZFUXNPDA-XQKSVPLYSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| child | LDLo | parenteral | 8290ug/kg (8.29mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: DECREASED MOTILITY OR CONSTIPATION BLOOD: CHANGES IN CELL COUNT (UNSPECIFIED) | Archives of Disease in Childhood. Vol. 51, Pg. 289, 1976. |
| child | TDLo | intravenous | 500ug/kg (.5mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ANOREXIA (HUMAN GASTROINTESTINAL: NAUSEA OR VOMITING | Journal of Pediatrics. Vol. 81, Pg. 90, 1972. |
| hamster | LD10 | parenteral | 350ug/kg (.35mg/kg) | Journal of Surgical Oncology. Vol. 15, Pg. 355, 1980. | |
| human | TDLo | intravenous | 120ug/kg/8W (.12mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) | British Medical Journal. Vol. 1, Pg. 1251, 1977. |
| mouse | LD50 | intraperitoneal | 1300ug/kg (1.3mg/kg) | Cancer Treatment Reports. Vol. 65, Pg. 1049, 1981. | |
| mouse | LD50 | intravenous | 3mg/kg (3mg/kg) | United States Patent Document. Vol. #4279915, | |
| mouse | LD50 | unreported | 5800ug/kg (5.8mg/kg) | Cancer Research. Vol. 46, Pg. 2703, 1986. | |
| mouse | LDLo | intratracheal | 1200ug/kg (1.2mg/kg) | Toxicology Letters. Vol. 30, Pg. 63, 1986. | |
| rat | LD50 | intraperitoneal | 1250ug/kg (1.25mg/kg) | Advances in Teratology. Vol. 3, Pg. 181, 1968. | |
| rat | LD50 | intravenous | 1mg/kg (1mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Journal of Medicinal Chemistry. Vol. 28, Pg. 1079, 1985. |
| women | TDLo | intravenous | 40ug/kg (.04mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS | Medical Journal of Australia. Vol. 143, Pg. 305, 1985. |
What can I do for you?
Get Best Price
